ArticleBlood2011
Differential and tumor-specific expression of CD160 in B-cell malignancies.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 53 citations in OpenAlex.
- MutantFrontiers in immunology · 2026Article
- Aberrant Expression ofCancers · 2025Article
- The integrated molecular and histological analysis defines subtypes of esophageal squamous cell carcinoma.Nature communications · 2024Article
- Effect ofInternational journal of molecular sciences · 2024Article
- Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy.Genes & diseases · 2024Review
- The Association Between Breast Cancer and Blood-Based Methylation ofFrontiers in genetics · 2022Article
- CD160 receptor in CLL: Current state and future avenues.Frontiers in immunology · 2022Review
- BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia.Cancers · 2021Article
- Expanded antigen-experienced CD160Journal for immunotherapy of cancer · 2021Article
- Measurable residual disease in the treatment of chronic lymphocytic leukemia.Journal of clinical and experimental hematopathology : JCEH · 2020Review
- A primer set for the rapid isolation of scFv fragments against cell surface antigens from immunised rats.Scientific reports · 2020Article
- CD160 expression on CD8Cancer immunology, immunotherapy : CII · 2020Article
- Evaluation of CD160 and CD200 Expression as Differentiating Markers between Chronic Lymphocytic Leukemia and Other Mature B-Cell Neoplasms.International journal of hematology-oncology and stem cell research · 2020Article
- Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay.Frontiers in oncology · 2020Article
- Consistency of the Moreau CLL score.Journal of clinical laboratory analysis · 2018Article
- Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.Molecular oncology · 2015Review
- Inhibitory receptors as targets for cancer immunotherapy.European journal of immunology · 2015Review
- Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia.Blood cancer journal · 2015Article
- Tumor necrosis factor superfamily in innate immunity and inflammation.Cold Spring Harbor perspectives in biology · 2014Review
- STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosis.Molecular cancer research : MCR · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
Abstract
CD160 is a human natural killer (NK)-cell-activating receptor that is also expressed on T-cell subsets. In the present study, we examined 811 consecutive cases of B-cell lymphoproliferative disorders (B-LPDs), and demonstrated CD160 expression in 98% (590 of 600) of chronic lymphocytic leukemia (CLL) cases, 100% (32 of 32) of hairy cell leukemia (HCL) cases, 15% (5 of 34) of mantle cell lymphoma (MCL) in the leukemic phase, and 16% (23 of 145) of other B-LPD cases. CD160 transcript and protein were absent in the normal B-cell hierarchy, from stem cells, B-cell precursors, maturing B cells in the germinal center, and circulating B cells, including CD5(+)CD19(+) B1 cells in umbilical cord. CD160 positivity was significantly higher in CLL and HCL in terms of percentage (65.9% and 67.8%, respectively, P < .0001) and median fluorescence intensity (552 and 857, respectively, P < .0001) compared with all other B-LPD cases. Lymph node CLL samples were also CD160(+). Using the disease-specific expression of CD5, CD23, and CD160, a score of 3 characterized CLL (diagnostic odds ratio, 1430); a score of 0 excluded CLL, MCL, and HCL; and the CD23/CD5 ratio differentiated CLL from leukemic CD23(+) MCL. In the B-cell lineage, CD160 is a tumor-specific antigen known to mediate cellular activation signals in CLL, and is a novel target for therapeutic manipulation and monitoring of minimal residual disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.